Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Osimertinib With Chemotherapy Improves OS in Patients With EGFRm NSCLC

Summary by Pharmacy Times
The combination regimen had stronger benefits in patients with locally advanced or metastatic epidermal growth receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC) than osimertinib alone.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

GeneOnline NewsGeneOnline News

Combining Osimertinib with Chemotherapy Improves Overall Survival in Advanced EGFR-Mutated NSCLC

A recent study has shown that combining osimertinib wit […] The post Combining Osimertinib with Chemotherapy Improves Overall Survival in Advanced EGFR-Mutated NSCLC first appeared on GeneOnline News. The post Combining Osimertinib with Chemotherapy Improves Overall Survival in Advanced EGFR-Mutated NSCLC appeared first on GeneOnline News.

Read Full Article
Pharmacy TimesPharmacy Times

Osimertinib With Chemotherapy Improves OS in Patients With EGFRm NSCLC

The combination regimen had stronger benefits in patients with locally advanced or metastatic epidermal growth receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC) than osimertinib alone.

Read Full Article
targetedonc.comtargetedonc.com

Strategic Advances in EGFR+ NSCLC: Navigating Evolving Treatment Paths With Dato-DXd

Jacob Sands, MD, discusses the inclusion of Dato-DXd into the treatment landscape of EGFR-mutant NSCLC.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

targetedonc.com broke the news in on Monday, July 28, 2025.
Sources are mostly out of (0)

Similar News Topics

News
For You
SearchBlindspotLocal